Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development
IMVT•Directional signals seen, with safety unchanged
Results showed favorable directional signals on several measures, with stronger antibody reductions linked to better clinical responses.
Safety and tolerability remained consistent with prior studies, with no new concerns highlighted.
Other IMVT-1402 development programs remain on schedule across multiple autoimmune diseases.
Study misses primary endpoint in cutaneous lupus
Immunovant reported topline results from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus.
The study missed its primary goal, prompting Immunovant to halt development of IMVT-1402 in this indication.
